Genetic capsid labeling of conditionally replicative adenoviruses (CRAds) with fl uorescent tags offers a potentially more accurate monitoring of those virotherapy agents in vivo. The capsid of an infectivity-enhanced CRAd, Ad5/3, delta 24, was genetically labeled with monomeric red fl uorescent protein 1 (mRFP1) or its advanced derivative, "mCherry," to evaluate the utility of each red fl uorescent reporter and the benefi t of CRAd capsid labeling for noninvasive virus tracking in animal tumor models by a new spectral imaging approach. Either reporter was incorporated into the CRAd particles by genetic fusion to the viral capsid protein IX. Following intratumoral injection, localization and replication of each virus in orthotopic breast cancer xenografts were analyzed by spectral imaging and verifi ed by quantitative polymerase chain reaction. Fluorescence in tumors increased up to 2,000-fold by day 4 and persisted for 5 to 7 weeks, showing oscillatory dynamics refl ective of CRAd replication cycles. Capsid labeling in conjunction with spectral imaging thus enables direct visualization and quantifi cation of CRAd particles in tumors prior to the reporter transgene expression. This allows for noninvasive control of CRAd delivery and distribution in tumors and facilitates quantitative assessment of viral replication. Although mCherry appeared to be superior to mRFP1 as an imaging tag, both reporters showed utility for CRAd imaging applications.
technologies offer a means to better understanding in vivo biology of CRAds and improving their therapeutic effi cacy.
The fi rst vector imaging applications, based on reporter transgene expression from a replication-defective viral genome, allowed visualization of viral infection in cells and proved feasibility of viral targeting to a specifi c cell population. 5 -8 Subsequently, expression of imaging transgenes from replicative virus genomes offered a tool for tracking viral replication and spread within the infected tissues. 9 However, the conventional vector imaging strategies, critically dependent on the viability of infected cells to generate a transgene expression-dependent imaging signal, are incompatible with the cell-killing function of oncolytic agents and, therefore, inadequate for assessment of CRAd accumulation and spread in tumors.
An alternate strategy to engineering of an imaging reporter into Ad vectors involves its genetic fusion with the viral minor capsid protein IX (pIX). This approach not only allows for coordinated expression of a reporter transgene with this virus-specifi c protein to mirror the onset of Ad replication 10 but also results in direct incorporation of an imaging modality in the viral capsid. 11 -14 This strategy holds a potential utility for detection and quantifi cation of viral particles in tumors prior to the onset of the virus-specifi c V IROTHERAPY WITH CONDITIONALLY REPLICA-TIVE ADENOVIRUSES (CRAds) represents a promising approach to treatment of cancer. Genetic manipulations with human adenovirus (Ad) have enabled cancer selectivity of viral replication as well as modifi cation of the Ad's natural tropism to enhance its infectivity for cancer cells. 1 Despite exciting preclinical data, adenoviral cancer gene therapy approaches have yet to display therapeutic effi cacy in human clinical trials. 2 Insuffi cient transduction of cancer cells by Ad and the lack of noninvasive methods of monitoring CRAd localization and replication in vivo represent major obstacles that hamper clinical improvement of the CRAd-based virotherapy approach. 2 -4 In that regard, noninvasive imaging gene expression and replication as well as direct tracking of the replicating viral mass in vivo. 11 , 15 Red fl uorescent reporters of the "mFruit" family with far-red emission spectra, such as mCherry, hold potential for live imaging in animal models of human diseases owing to deeper tissue penetration and higher photostability of their fl uorescence. 16 Among the monomeric red fl uorescent proteins, derivatives of Discosoma sp protein DsRed, mCherry offers the longest wavelength fl uorescence (only 3 nm longer than monomeric red fl uorescent protein 1 [mRFP1]), higher photostability (t 0.5 to bleach = 68 seconds vs 6.2 seconds for mRFP1), and brightness of the signal (27% of DsRed vs 21% for mRFP1), as well as faster maturation time (15 minutes versus < 1 hour for mRFP1) and higher tolerance to N-terminal fusions compared to mRFP1. Despite a slightly lower quantum yield (0.22 vs 0.25 for mRFP1), these characteristics altogether make mCherry a superior imaging modality to mRFP1 owing to a more robust predicted fl uorescence yield. 17 , 18 One of the obstacles for in vivo imaging of the red fl uorescent reporters is a background autofl uorescence, which is an intrinsic property of mammalian cells, tissues, and diet and is indistinguishable from the red fl uorescence of protein reporters by the traditional fl uorescent imaging technique. 19 A new spectral imaging technology enables specifi c detection of fl uorescent reporters in animal cells and tissues by their distinct spectral profi les. Special image processing software can then "unmix" spectral profi les of fl uorescent reporters from those of autofl uorescence and "extract" a specifi c signal component from a digital image. 20 The technical feasibility of genetic capsid labeling of Ad vectors has been established, 11 -13 , 15 , 21 -23 and replication-competent Ads with red fl uorescent tags on the capsid, including mRFP1, have recently been generated 15 , 23 and validated in vivo by a conventional fl uorescent imaging approach. 15 However, the benefi ts of Ad capsid labeling for in vivo imaging applications have not been demonstrated directly. On the other hand, to our knowledge, no capsid-labeled CRAd agent has been reported to date, except the ones generated in our most recent study. 23 Moreover, no capsid-labeled CRAd has ever been evaluated in vivo for imaging potential.
In the present study, we sought to develop a novel CRAd, fl uorescently labeled with a new-generation red fl uorescent reporter mCherry, and to evaluate mCherry as a CRAd imaging modality relative to its ancestor mRFP1 in a mouse model of breast cancer using a new spectral imaging technique. The capsid labeling modifi cations were introduced in the genome of the infectivity-enhanced CRAd, known as Ad5/3, delta 24, with previously demonstrated strong oncolytic potential in animal models of cancer. 24 The present study for the fi rst time demonstrates the utility of Ad capsid labeling for direct visualization of the CRAd in tumors immediately after its intratumoral (IT) administration as well as the utility of spectral imaging as a tool for distinguishing the virus-associated fl uorescence from background autofl uorescence and noninvasive tracking of CRAd replication in tumors. Potential implications of the spectral imaging technology for clinical and basic research are discussed.
Materials and Methods

Cells
Breast cancer cells DY36T2 and 2LMP were maintained in modifi ed improved minimal essential medium (MEM), (GIBCO, Gaithersburg, MD), supplemented with 10% fetal bovine serum (FBS). Human fi broblasts VH-10 were grown in Dulbecco's Modifi ed Eagle's Medium (DMEM, HyClone Laboratories, Logan, UT); MCF7 and LCC6 breast cancer cell lines were maintained in an alpha-modifi ed MEM (Mediatech, Manassas, VA); MDA-MB-231, MDA-MB-468, and MDA-MB-435* 25 breast cancer cells were grown in lowglucose DMEM (HyClone Laboratories), supplemented with MEM vitamins, MEM nonessential amino acids, and 1 mM sodium pyruvate; BT-474 breast cancer cells were maintained in RPMI-1640 medium (Mediatech) supplemented with 10 µg/mL insulin, 4.5 g/L glucose, 10 mM HEPES, and 1 mM sodium pyruvate; human embryonic kidney 293 (HEK 293) cells (Microbix, Toronto, ON) and A549 lung adenocarcinoma cells were cultured in DMEM/F12 (50:50) (Mediatech). All media were supplemented with 10% FBS (HyClone Laboratories), 2 m M L -glutamine, 100 IU/mL penicillin, and 100 µg/mL streptomycin (all Mediatech). All cells were grown in monolayers in plastic fl asks at 37°C in a humidifi ed atmosphere with 5% CO 2 .
Recombinant Ad Construction
The genome of the CRAd with mCherry red fl uorescent protein on the capsid was constructed by homologous recombination in Escherichia coli (BJ5183 strain) 26 , 27 using a fi ber gene-modifi ed AdEasy-1 backbone vector AdEz-F5/3 (Ad5D E1 /D E3 -F5/3) 14 and a modifi ed pShuttle vector pSlD24-pIX-mCherry. This shuttle vector contained the mCherry coding sequence, inserted downstream of the Ad5 minor capsid pIX gene to generate a C-terminal pIX fusion and a 24-basepair deletion in the Ad5 E1A gene coding sequence (delta 24). 28 The plasmid with mCherry reporter coding sequence, kindly provided by Dr. Roger Tsien (Howard Hughes Medical Institute, University of California, San Diego, La Jolla, CA), was used to amplify mCherry open reading frame by polymerase chain reaction (PCR) using the following sense and antisense primers: 5′-ATTAGCTAGCCGGAATGGTGA-3′ and 5′-TATG ACTA GTCGAC TTACTTGTACAGCTCGTCCATGCCG-3′ ( Nhe I site is underlined, Sal I site is shown in bold, Spe I is shown in italics). The resulting product was digested with Nhe I and Spe I (generates Nhe I -compatible cohesive ends) and subcloned into the unique Nhe I site of the pSlD24,pIX-tk 23 by replacing the HSV-tk (tk) gene coding sequence. Construction of the control virus with mRFP1 instead of mCherry and the corresponding shuttle vector pSlD24-pIX-mRFP1 derived from the previously described pScsD24 29 was recently reported elsewhere. 23 Both shuttle vectors carried a linker sequence, encoding a 10-amino acid peptide (SA DYKDDDDK ) with an octapeptide fl ag motif (shown in bold), inserted downstream of the polypeptide IX coding sequence in place of the stop codon, followed by Nhe I (pSlD24-pIX-mCherry) or Bam H1 (pSlD24-pIX-mRFP1) restriction sites. Following homologous recombination and colony selection on kanamycin, the recombinants were screened by a recombinant-specifi c PCR assay of our own design (unpublished data, 2007) and verifi ed by partial sequencing. Following a restriction test ( Hind III , Nhe I ), DNA isolated from positive clones was linearized with Pac I and transfected into the HEK 293 helper cells with lipofectamine LTX (Invitrogen, Carlsbad, CA). The expression of pIX fusions was under the control of the native pIX promoter. The deletion of the E3 genomic region, including nucleotides 28,133-30,817, was described previously. 14
Generation and Molecular Validation of CRAds
All viruses were generated and plaque-purifi ed in E1complementing retinoblast 911 cells according to standard procedures. 30 The CRAds were propagated in A549 adenocarcinoma cells, whereas the replication-defective virus was amplifi ed in helper HEK 293 cells. All viruses were purifi ed by double cesium chloride (CsCl) ultracentrifugation (AdEasy system, Qbiogene, Carlsbad, CA) and dialyzed against phosphate-buffered saline (PBS) containing 0.5 mM Mg 2+ , 0.9 mM Ca 2+ , and 10% glycerol. Purifi ed preparations of each virus were analyzed for viral particle titer, determined by absorbance at 260 nm (A 260 ) using a conversion factor 1 A 260 = 1.1 × 10 12 vp/mL, as described earlier. 31 The genomic identity of each virus was verifi ed by conventional PCR assays and sequencing of some PCR products. (The PCR primer sequences used in those assays are available on request.) The absence of contamination with the wild-type E1A sequencecontaining genomes (replication-competent adenovirus [RCA]) in virus preparations was confi rmed by an in-house developed PCR assay of our own design (unpublished data, 2007) . Incorporation of pIX-mRFP1 and pIX-mCherry fusion proteins in the viral capsids and their molecular integrity were confi rmed by Western blot. Equal amounts (1 × 10 10 vp) of each virus were subjected to SDS-PAGE gel electrophoresis and transferred onto a polyvinylidene fl uoride (PVDF) membrane. The membrane was blocked and hybridized with a 1:1,000 dilution of mouse monoclonal ANTI-FLAG M2 primary antibody (Sigma, St. Louis, MO) for 1 hour. The membrane was washed in Tris-buffered saline-Tween and incubated with a secondary horseradish peroxidase-conjugated sheep antimouse antibody diluted 1:1,000 (Amersham Biosciences, Piscataway, NJ) for 1 hour. For normalization, the same PVDF fi lters were rehybridized with monoclonal (4D2) antibodies against an Ad5 fi ber tail at 1:5,000 dilution. Antibody binding was detected using an electrogenerated chemiluminescence (ECL) detection system (GE Healthcare, Piscataway, NJ). Hybridization procedures were performed using a Western breeze kit (Invitrogen, Carlsbad, CA). For molecular-weight reference, prestained protein standards (Bio-Rad, Hercules, CA) were used.
Infectious titers were determined in HEK 293 helper cells by the 50% tissue culture infectious dose (TCID 50 ) method. The limiting dilution end point and infectious titer (TCID 50 /mL) were determined by the Kärber equation: TCID 50 /mL = 10 [1 + D(S-0.5)] / V , where D is the logarithm of the dilution factor (eg, D = 1 for the 10-fold serial dilution), S is the logarithm of the initial dilution plus the sum of ratios of infection-positive wells per total wells at each subsequent dilution, and V is the volume of the diluted vector (in mL) used for inoculation.
In Vitro Screening of Breast Cancer Cells for CRAd Infection and Replication
Nine different breast cancer cell lines, mentioned above, were infected with the mCherry-labeled CRAd at the multiplicity of infection (MOI) of 1 TCID 50 /cell and subjected to fl uorescent microscopy analysis 48 hours later. To assess the cytotoxic effect of the oncolytic agents on each cell line, the same CRAd-infected cells were further incubated for 2 weeks and stained with 0.2% crystal violet dye in buffered formalin for 20 minutes followed by multiple washes with water.
In Vitro Analysis of CRAd Cell Binding and Replication by Real-Time PCR
DY36T2 or MDA-MB-361 cells were incubated with the labeled viral particles at 4°C at an MOI of 1.5 × 10 4 vp/cell to synchronize the infection process at the receptor-binding step. Virus binding to cell membranes was visualized by fl uorescence microscopy using an inverted IX-70 microscope (Olympus, Melville, NY), equipped with a Magnifi re digital charge-coupled device camera (Optronics, Golets, CA) 5 to 10 hours postinfection. Images were taken with 40× objective using red (mCherry or mRFP1) and blue (Hoechst) excitation fi lters. Images were overlaid by Adobe Photoshop C2 software. CRAd internalization and traffi cking through the cytoplasm to the nuclei were observed 2 to 5 hours after changing cell incubation temperature from 4° to 37°C.
Cell binding of mRFP1-and mCherry-CRAds was further compared by quantifi cation of Ad genomic DNA recovered from the infected cells. Specifi cally, DY36T2 or MDA-MB-361 cells were plated in 12-well plates in the recommended media and grown to 90% confl uency. Each cell line was infected with the mCherry-CRAd or the mRFP1-CRAd at an MOI of 500 vp/cell. After 1 hour of infection at 4°C, the cells were washed three times with PBS to remove the unbound virus. Next, total DNA was isolated from infected cells using a DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA). Quantitative real-time polymerase chain reaction (qPCR) for the E4 region of the Ad5 genome was then performed to determine the number of bound infectious particles. The following primers were used for amplifi cation of the Ad5 E4 region: 5′-GGAGTGCGCCGAGACAAC-3′ (forward) and 5′-ACTACGTCCGGCGTTCCAT-3′ (reverse). Detection was performed with the following probe: 6FAM-TGG CATGACACTACGACCAACAC-TAMRA. A housekeeping β-actin gene was used for normalization. For replication analysis, DY36T2 or MDA-MB-361 cells were infected at an MOI of 100 vp/cell and harvested 12, 24, and 60 hours postinfection. All other experimental details were exactly as described above for the cell binding experiment.
Generation of Orthotopic Xenografts in Nude Mice
Female athymic mice, 6 weeks of age (Frederick Animal Production Program, Frederick, MD), were allowed to acclimate at the University of Alabama for 2 weeks before use. Strict adherence to the University of Alabama at Birmingham Institutional Animal Care and Use Committee-approved protocol was maintained throughout the study. MDA-MB-361 or DY36T2 breast cancer cells (5 × 10 7 ) in sterile PBS (100 µL) were injected into the mammary fat pads of 3% isofl urane-anesthetized mice to orthotopically implant xenografts. Tumors were allowed to grow for 2 weeks to become approximately 5 mm in diameter before they were used for in vivo experiments.
Spectral Imaging of CRAds
Orthotopic breast carcinoma tumors, resulting from orthotopic implantation of DY36T2 or MDA-MB-361 cells, were directly injected with 3 × 10 10 vp of either mCherry-CRAd or mRFP1-CRAd. Prior to IT virus injection, background autofl uorescence images of each tumor were collected. Tumors were imaged 5 minutes and 1 hour after virus injection using a Leica MZFLIII fl uorescent stereomicroscope (Meyer Instruments, Inc., Houston, TX), equipped with a HQ560/55xHQ excitation fi lter and a 600LP emission fi lter and a "Nuance" spectral imaging camera N-MS1-500-FL (CRI, Inc., Woburn, MA). A liquid-crystal tunable wavelength fi lter in the camera was set for collection of emission images from 600 to 720 nm in 5 nm increments. To enable comparison across time points and avoid potential signal saturation, the spectral imaging data sets (600-720 nm) were collected at 100-, 400-and 5,000-millisecond exposures per image, using 4 × 4 binning for fl uorescence and 1 × 1 binning for bright fi eld images. All tumors were imaged twice weekly for the duration of the experiment, after the initial data collections.
Composite images (unmixed composites) were generated for each tumor by unmixing the spectral signature of the red fl uorescent reporter fusion proteins (pIX-mCherry or pIX-mRFP1) from those of background autofl uorescence using a spectral library that was compiled from numerous spectral profi les collected from uninjected control tumors under the same conditions.
The original image of each tumor at a given time point was analyzed using the Nuance 2.4.2 image quantifi cation software (CRI, Inc) after extraction of its 630 nm component (excitation maximum, shifted in the pIX fusions from the 607 to 610 nm excitation maximums of the red fl uorescent proteins) and normalizing signals as photons per millisecond of exposure. Background autofl uorescence of each 630 nm wavelength image was quantifi ed within three different locations outside the tumor area of the same image, and the mean value was subtracted from the tumor fl uorescence. Of note, data for one mouse from each group with the DY36T2 tumors were excluded from the charts, presented in Figure 6 , for technical reasons.
To take into account lower infectious titer of the mCherry CRAd compared to mRFP1-CRAd, all fl uorescence intensity values obtained in tumors with replicating CRAds (from day 4 until the last day of the experiment) were normalized to equal the number (1 × 10 9 ) of infectious (TCID 50 ) units per tumor.
The effi ciency of CRAd capsid labeling (pIX incorporation) was assessed by quantifi cation of fl uorescent signals, emitted by 10 10 CsCl-purifi ed particles of each capsid-labeled virus in 10% glycerol containing dialysis buffer (10 mM Tris-HCl; pH 8.0; 50 mM NaCl; 2 mM MgCl 2 ) sampled on a glass slide, using the same approach as above. Unlabeled pIX-WT CRAd was used as a nonfl uorescent virus/background control.
Statistical Analysis
All values were compared between groups (mCherry vs mRFP1) or (DY36T2 vs MDA-MB-361) by nonparametric Mann-Whitney test using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA). The differences were assumed to be statistically signifi cant when the p values were £ .05.
Results
Construction and Molecular Validation of the mCherry-Labeled CRAd
To achieve capsid labeling of an infectivity-enhanced CRAd, Ad5/3-delta 24, with a fl uorescent tag, optimal for in vivo imaging applications, a red fl uorescent protein mCherry was genetically fused to the C-terminus of the Ad minor capsid pIX. To facilitate transduction of tumors, this virus also carried a fi ber modifi cation, genetically replacing the C-terminal "knob" domain of the Ad5 fi ber with its counterpart from the Ad serotype 3 (Ad3) fi ber. 24, 30 In addition, the entire E3 region of the Ad genome was deleted to prevent genomic instability of the pIX-modifi ed virus (see Discussion). 32 , 33 A previously reported CRAd with mRFP1 on the capsid 23 was evaluated in this study in parallel as an isogenic variant with an alternate imaging modality.
Infectious viral particles of either the mCherry-( Figure 1A ) or the mRFP1-labeled CRAd (data not shown) preparations represented a predominant fraction (lower band) on CsCl-density gradients. Fluorescent labeling of the viral particles was indicated by the pink color of the purifi ed virus bands, visible even without fl uorescence imaging. Capsid labeling of each CRAd was further evidenced by strong fl uorescence of the purifi ed virus solutions, sampled on a glass slide, whereas a CRAd with wild-type pIX (pIX-WT CRAd) showed no fl uorescence ( Figure 1B by quantifi cation of viral particle-associated fl uorescence (see Figure 1B , chart), as well as by Western blot analysis ( Figure 1C ). Subsequent detection of the modifi ed fi ber protein on the same blots verifi ed that an equal number of viral particles were used for comparison ( Figure 1D ). These experiments demonstrated similar capsid incorporation effi ciencies of the pIX-mCherry and pIX-mRFP1 fusions. Furthermore, Coomassie gel staining showed comparable amounts of other Ad capsid proteins, suggesting that capsid labeling did not affect incorporation of other structural proteins into the viral particles and the CRAd capsid assembly (data not shown).
In Vitro Selection of Breast Cancer Cells for Establishing In Vivo Xenograft Tumor Models
To establish an optimal animal model of human breast cancer for in vivo CRAd imaging studies, a panel of available breast cancer cell lines were analyzed for their ability to be infected with and support replication of the capsid-labeled infectivity-enhanced CRAd Ad5/3-delta 24-pIX-mCherry (mCherry-CRAd) using fl uorescence microscopy. Cell lines DY36T2 and MCF7 displayed the highest levels of fl uorescent labeling ( Figure 2 ). The strong fl uorescence in DY36T2 and MCF7 cells, indicative of effi cient CRAd infection and replication, correlated with high susceptibility of those cells to the CRAd-mediated oncolysis. The latter was evidenced by early development of cytopathic effect (see Figure 2 , bright fi eld images) followed by an effi cient killing of the infected cells 2 weeks later, as revealed by crystal violet assay (data not shown). Conversely, a relatively weak fl uorescence observed in BT-474, MDA-MB-231, and MDA-MB-361 cell lines was consistent with the absence of cell-killing effect or its dramatic delay compared to the DY36T2-infected cells (see Figure 2 and data not shown). On the basis of these observations, DY36T2 and MDA-MB-361 cells lines were chosen as highly susceptible for (positive) and resistant to (negative) the Ad5/3-delta-24 CRAd transduction and/or replication, respectively. The choice was also based on the known ability of these cells to grow in vivo and generate orthotopic mammary fat pad tumors in athymic nude mice.
Biologic Characterization and Comparison of the Capsid-Labeled CRAds In Vitro
The labeled CRAd particles demonstrated the ability to bind to cell surface receptors, as revealed by fl uorescent labeling of the chosen target cells, following several hours of incubation with an excess of purifi ed viruses at 4°C ( Figure 3 ). These conditions allow receptor binding but not internalization step of the Ad infection. Furthermore, gradual translocation of the cell surface-associated fl uorescence fi rst to the cytoplasm and then to the nuclei of the infected cells was observed on changing the cell incubation temperature from 4° to 37°C (data not shown). The ability of the fl uorescent CRAds to bind cell surface receptors with subsequent internalization and intracellular traffi cking confi rmed the full biologic activity of the capsid-modifi ed particles. Of note, the mRFP1-generated cell surface fl uorescence bleached out detectably faster than that produced by the mCherry tag on prolonged exposure of the culture cells to the excitation light (data not shown). The physical (viral particle) titers of the mCherry-and the mRFP1-CRAds were similar (3.2 × 10 12 and 4.3 × 10 12 vp/mL, respectively) and only slightly lower than that of unmodifi ed control pIX-WT CRAd (6 × 10 12 vp/mL), suggesting only a minor, if any, effect of the pIX modifi cations on the CRAd production. In contrast, the infectious titer of the mCherry-CRAd (1.66 × 10 10 TCID 50 /mL) was sixfold lower than that of the mRFP1 virus (1 × 10 11 TCID 50 /mL) ( p = .017). Lower infectivity was observed for several independent preparations of the mCherry-CRAd. In line with this fi nding, the intensity of red fl uorescence in mCherry-CRAd-infected cells was signifi cantly lower ( p = .008) compared to the mRFP1-CRAdinfected cells ( Figure 4 , A and B) .
To verify the difference in infectivity by molecular methods, equal numbers of the mCherry-and the mRFP1-CRAd particles were compared for their ability to bind to the selected breast cancer culture cells using a real-time qPCR approach. The results demonstrated 3.35-fold ( p = .002) and 3-fold ( p = .01) more particles of the mRFP1-CRAd bound to DY36T2 and MDA-MB-361 cells compared to the mCherry-CRAd particles, respectively ( Figure 4C ). On the other hand, approximately twice as many particles of the mRFP1-( p = .021) and the mCherry-CRAds ( p = .01) were bound to MDA-MB-361 cells than to DY36T2 cells (see Figure 4C ), suggesting that the former cells express approximately twice as much Ad3 receptor.
To further verify the difference in infectivity between the viruses, DNA replication of the mCherry-and the mRFP1-CRAds was compared in each cell type at various times following infection with an equal number of particles of each virus. Both CRAds showed a robust amplifi cation of genomic DNA between 24 and 72 hours postinfection, which, according to our pilot study data (not shown), corresponded to the linear portion of the CRAd growth curves. In line with the observed difference in infectious titers, the mRFP1-CRAd produced increasingly more genomic DNA in DY36T2 cells over time compared to the mCherry-CRAd ( Figure 4D ). The calculated differences between the amplifi ed mRFP1and the mCherry-CRAd genomes in DY36T2 cells at 24 and 60 hours postinfection were 2.4-fold ( p = .014) and 12.2fold ( p = .132), respectively. Replication of both CRAds in MDA-MB-361 cells was substantially attenuated as a detectable increase in the genomic DNA occurred only 24 hours postinfection and the amount of both CRAd genomes at 60 hours postinfection was over 100-fold lower ( p = .01) than in the DY36T2 cells (see Figure 4D ). Thus, the lower number of particles bound to each cell type and fewer replicated CRAd genomes, resulting in reduced reporter gene expression and fl uorescence in the infected cells (see Figure 4A ), were DY36T2 and MDA-MB-361 cell lines (highlighted in red ) were chosen for implantation in mice to generate tumor xenografts. The asterisk indicates that the origin of the MDA-MB-435 cell line is highly controversial and was recently suggested to be a melanoma rather than a breast cancer line. However, the controversy has not been fully resolved. 25 consistent with the lower infectious titer of the mCherry-CRAd observed by the TCID 50 method.
As predicted, adjusting the number of the mCherry-CRAd infectious particles by a factor of 6 (the CRAd infectious titer ratio) resulted in nearly equal levels of fl uorescence in the CRAd-infected cells between 48 and 60 hours postinfection ( Figure 4E ). This experiment suggested that during the linear phase of the CRAd replication in vitro, the level of intracellular fl uorescence is almost proportional to the number of infectious viral particles used for infection.
Direct Visualization of Tumor-Injected Labeled Viral Particles by Spectral Imaging
This part of the study was aimed at evaluation of CRAd capsid labeling as a tool for direct visualization and quantifi cation of the oncolytic agents in tumors shortly after their direct IT administration as a means to control the accuracy of virus delivery and IT distribution. In this regard, we employed spectral imaging as a unique technology, capable of distinguishing a specifi c fl uorescent signal associated with the labeled viral particles from autofl uorescence background. A specifi c red fl uorescence could be detected in orthotopic mammary fat pad tumors (~5-7 mm in diameter) following IT injection of 3 × 10 10 fl uorescently labeled viral particles. These imaging experiments also revealed high tumor-totumor variability in the input signal intensity ( Figure 5 ).
Although the intensity of the virus-associated fl uorescence in most injected tumors was high enough to be clearly visualized without the spectral "unmixing" procedure (see Figure 5A , panel M #3; see Figure 5B , panel M #4), in some tumors, this image-processing step was absolutely critical for distinguishing the virus-associated fl uorescence from background autofl uorescence (see Figure 5A , panel M #1; see Figure 5B , panel M #2). Quantifi cation of fl uorescence emitted by the tumor-delivered CRAds revealed only a subtle, up to twofold decrease in signal intensity within 1 hour following virus administration (see Figure 5 , panels M #2, M #3, M #4, bar graphs) in most tumors, suggesting diffusion of the CRAds from or redistribution within the tumor via tumor vasculature and/or owing to viral particle disintegration. 
Live Tracking of CRAd Replication in Orthotopic Breast Cancer Mouse Models
The replication dynamics of each CRAd in orthotopic DY36T2 or MDA-MB-361 xenografts was analyzed by repetitive noninvasive spectral fl uorescence imaging of the mRFP1 or mCherry reporters and signal quantifi cation for each time point in each individual tumor. We observed a marked increase in red fl uorescence in DY36T2 tumors after injection of either mCherry ( Figure 6A , Figure 7A ) or mRFP1 ( Figure 7B ) CRAds. Despite some variations in signal intensity among tumors of each experimental group, the major peaks of fl uorescence were consistently observed in all injected DY36T2 tumors between days 4 and 7 as well as between days 10 and 14 after virus administration. These were invariably followed by a sharp signal decrease on day 17. Another minor peak of intensity in the DY36T2 tumors was consistently observed around day 21 (see Figure 7 , A and B) . Unexpectedly, tumors derived from the MDA-MB-361 cells that were less permissive for the CRAd replication in vitro (see Figure 4 , A-D) produced a substantially stronger fl uorescence in vivo than the DY36T2-derived tumors (see Figure 6B and Figure 7 , C and D). The CRAd fl uorescence profi les in the MDA-MB-361 tumors were discernibly different from those in the DY36T2 tumors. Although the position of the major peak was the same as in DY36T2 tumors (day 4), this peak was sharper in the MDA-MB-361-derived tumors.
The second fl uorescence peak in the MDA-MB-361 tumors occurred between days 15 and 20, followed by a sharp signal decrease on day 24 (see Figure 7 , C and D). Despite the strong variability in signal intensity, the relative position of both peaks was consistent among all tumors within each experimental group. Three additional peaks were observed on days 28, 35, and 42, indicating productive CRAd replication even at later time points. A specifi c fl uorescent signal could still be detected in each tumor type for as long as 38 to 49 days after a single dose injection of each virus (see Figure 6 and Figure 7 ) .
In contrast to MDA-MB-361 tumors, the level of fl uorescence in tumors derived from other breast cancer cell lines (MDA-MB-231 and 2LMP) with low in vitro permissiveness for the CRAds was dramatically lower (see Figure 6C ) and in line with the in vitro results.
Owing to the fact that the mCherry-CRAd showed a sixfold lower infectivity than the mRFP1-CRAd but equal intensity of capsid labeling, a direct comparison of fl uorescent yields of the two in vivo replicating CRAds would be inadequate. In this regard, to estimate relative fl uorescence yields of each CRAd during its replication in tumors, we reasoned that signal intensities, measured for each time point of CRAd replication (on day 4 and thereafter), could be normalized to an equal number of infectious CRAd particles per tumor. The validity of such adjustment was rationalized by the following two assumptions: (1) the fl uorescence level in infected cells/tumors is proportional to imaging reporter gene expression, which, in turn, is proportional to the number of replicated viral genomes, and (2) the fl uorescence profi les observed in vivo for each CRAd and tumor type between 24 and 96 hours (4 days) following CRAd infection correspond to the linear phase of the CRAd growth curves in vitro and, therefore, are directly proportional to the number of infectious viral particles used for tumor transduction. These assumptions were based on the results of fl uorescence microscopy and the CRAd DNA replication in vitro analyses presented in Figure 4 .
Comparison of the infectious units-normalized signals revealed 11-fold ( p = .028) and a 3.6-fold ( p = .032) higher fl uorescence yields for the mCherry-CRAd compared to the mRFP1-CRAd in DY36T2 (see Figure 7 , A and B) and MDA-MB-361 tumors (see Figure 7 , C and D), respectively. On the other hand, whereas the mCherry-CRAd produced, on average, only 7.6fold ( p = .016) stronger signals in the MDA-MB-361 tumors compared to the DY36T2 tumors (see Figure 7 , A and C), the mean intensity of the major peaks for the mRFP1-CRAd replication profi les was 24-fold higher ( p = .016) in MDA-MB-361 tumors (see Figure 7 , B and D).
Whereas maximal amplifi cation of the signal in the DY36T2 tumors injected with the mCherry-CRAd was, on average, 263-fold (see Figure 7A ), the mRFP1-CRAd showed only a 23-fold signal increase (see Figure 7B ). In contrast, the average fl uorescence increase in MDA-MB-361 tumors was approximately 2,000-fold (see Figure 7C ) and 546-fold (see Figure 7D ) for the mCherry-and the mRFP1-CRAds, respectively .
Ex Vivo Analysis of Isolated and Sliced Tumors by Spectral Imaging
Imaging of surgically removed tumors revealed a high level of tissue-associated autofl uorescence background ( Figure 8C ). Spectral imaging was also found critical for identifi cation and localization of the specifi c, virus-associated red fl uorescence in isolated (see Figure 8 , panels M #2, M #3) or isolated and sliced (see Figure 8 , panels M #6, M #7, M #8) tumors as well as signal quantifi cation (data not shown). No statistically signifi cant difference in signal intensity was observed between the tumors before ("intact tumor") and after their surgical removal ("removed tumor") (see Figure 8 , panels M #2, M #3). In contrast, substantially stronger signals were measured in the same tumors after slicing ("removed and sliced tumor" on Figure 8 , panels M #6, M #7, M #8), suggesting that the intensity of in vivo detected signals is largely dependent on the location of the signal (virus-infected cells) relative to the tumor surface. Importantly, ex vivo imaging of the sliced tumors revealed a substantial signal distribution across the tumor mass. Nevertheless, no tumors showed viral spread throughout the entire tumor volume (see Figure 8 , panels M #6, M #7, M #8), suggesting limited CRAd lateralization.
Quantifi cation of CRAd Genomes in Tumors at Various Times Post-Virus Administration
To obtain direct evidence for CRAd replication in tumors on the molecular level, the viral genomic DNA was specifically detected and quantifi ed by real-time qPCR in the wholetumor lysates prepared on the last day of the experiment (days 38/41 for the DY36T2 tumor groups and days 45/49 for the MDA-MB-361 tumor groups) as well as from the tumors of each experimental group on day 4 and day 10 post-virus administration. The tumors representing these earlier time points of the experiment were part of each experimental group from the beginning of the study but removed on days 4 and 10 post-virus administration for ex vivo tumor imaging (tumors M #6, M #7, and M #8 on Figure 8 ) and subsequent CRAd genome quantifi cation. Comparison of the CRAd genomic DNA content in tumors at three different time points (day 4, day 10, and the last day) demonstrated a close correlation between the intensity of fl uorescent signal and the amount of the tumor-contained virus (data not shown), thereby supporting CRAd replication in the xenografts.
Discussion
The aim of this study was to develop a conditionally replicative adenovirus (CRAd) carrying an advanced-generation red fl uorescent reporter mCherry on its capsid and to evaluate the utility of this reporter for in vivo imaging of oncolytic agents by using a new spectral imaging technique as well as the benefi ts of the CRAd capsid labeling strategy for in vivo CRAd imaging applications. Use of mCherry as an imaging tag on the CRAd capsid was rationalized by the advanced optical characteristics of this fl uorescent reporter, established by previous studies. 18 Although mCherry was recently employed for genetic labeling of human immunodefi ciency virus 1 (HIV-1) 34 , it has not been used in the context of Ad capsid labeling or any Ad-based vectors.
The new oncolytic agents generated in this study on the basis of the Ad5/3-delta 24 CRAd carried either mRFP1 or mCherry fl uorescent proteins, genetically fused to the Ad structural pIX, represented by 240 copies per Ad5 capsid. To achieve cancer targeting of viral replication, both CRAds carried a 24-basepair deletion in the E1A gene that abolishes its binding to tumor suppressor protein retinoblastoma (Rb). This deletion prevents the E1A -mediated induction of the cell proliferation mechanism, necessary for the onset of Ad replication during the Ad5 infection of normal cells. As a result, the delta 24 mutation renders Ad replication selective for cancer cells with the defective Rb/p16 signaling pathway, where Rb blocking is no longer required to induce the Ad replication-permissive state. 28 In addition, both capsid-labeled CRAds carried a "serotype chimera" fi ber modifi cation (F5/3), providing one of the strongest known infectivity enhancement effects in most types of cancer cells both in vitro and in vivo. 24,31 , 35 Replacement of the fi ber knob domain with its counterpart from the Ad3 results in ablation of the natural coxsackie and adenovirus receptor (CAR) tropism and retargeting of the virus to a different set of receptors, currently believed to be CD46 and/or CD80/86. 36 , 37 Finally, both CRAd genomes had a fully deleted E3 region to avoid viral DNA packaging constraints, known to result from the lack or underincorporation of pIX in the Ad capsids, and to prevent possible genomic instability of the pIX-modifi ed virions. 32 , 33 Although capsid-labeled Ads with replicationdefective and replication-competent genomes have been described, 11 -13 , 15 , 21 , 22 the viruses generated in this and another recent study of ours 23 are, to the best of our knowledge, the fi rst reported CRAd agents with imaging tags on the capsids. This study also provides the fi rst imaging validation of a capsid-labeled CRAd in an orthotopic animal model of cancer.
The biologic properties of the labeled CRAd particles have been characterized, and no discernible defects in their assembly were found as a result of pIX-mCherry or pIX-mRFP1 incorporation in the CRAd capsids. Importantly, the effi ciency of incorporation of each fusion protein into the viral capsids and the resulting effi ciency of capsid-associated red fl uorescence were comparable between the two CRAds (see Figure 1 , B-D). Besides, the modifi ed CRAd particles were biologically active, as evidenced by their ability to fl uorescently label cell surface receptors (see Figure 3 ) with subsequent internalization and intracellular traffi cking of the labeled capsids or their fl uorescent components.
However, for unknown reasons, the infectious titers of the mCherry CRAd preparations were lower than those of the mRFP1 virus. Owing to the high degree of similarity in size and structure between mCherry and mRFP1 protein tags, the presence of mCherry per se was unlikely to account for the observed loss of infectivity. In fact, the pIX-mCherry fusion is slightly longer than pIX-mRFP1 partially owing to a slightly longer linker sequence between the fl ag and the fl uorescent protein. Although the linker size difference is negligible, the sequence of the linker peptide is different from that in the mRFP1 fusion and could possibly impose some adverse effect on the pIX-mCherry fusion structure and/or stability. Some evidence for its effect on stability comes from the smeary appearance of the pIX-mCherry band on the Western blot (see Figure 1C ). Degradation of the fusion could potentially result in its underincorporation or partial loss from the particles, which would reduce fl uorescence of the mCherry-CRAd particles. Although pIX-free Ad particles are known to be noninfectious, 32 , 33 this explanation is not consistent with our results of quantifi cation of capsid-associated fl uorescence (see Figure 1B ). After all, it is not clear if the lower infectious titers have any genetic determination at all.
Whereas the fl uorescence microscopy approach failed to detect any difference between mRFP1-and mCherry-CRAds in their cell-binding ability at 4°C (see Figure 3 ), a more sensitive qPCR-based approach revealed approximately three times more particles of the mRFP1-CRAd bound to both types of breast cancer cells (see Figure 4C ) at the same MOI (viral particle/cell). This fi nding agreed with higher infectivity of the mRFP1-CRAd preparation, which was also consistent with the higher number of replicated viral genomes (see Figure 4D ) and a discernibly stronger fl uorescence observed in the mRFP1-CRAd-infected cells 48 hours postinfection (see Figure 4 , A and B) . A barely detectable fl uorescence in the cells infected with a nonreplicative mRFP1-labeled control virus Ad5 d E1 pIX-mRFP1 (see Figure 4 , A and B) supported replication dependence of the fl uorescent signal in the CRAd-infected cells. This observation was consistent with an earlier study demonstrating a correlation between mRFP1 fl uorescence and replication of a capsid-labeled Ad carrying wild-type E1 genes. 15 In contrast to the cell surface-labeling assay, a PCRbased cell-binding analysis was able to demonstrate that MDA-MB-361 breast cancer cells can bind twice as many CRAd particles compared to DY36T2 cells (see Figure 4C ). This suggested that lower fl uorescence intensity produced in the CRAd-infected MDA-MB-361 cells 48 hours postinfection in vitro ( Figure 4, A and B) was rather due to the lower rate of the delta 24 CRAd replication in these cells than to the lack of the Ad3 receptor and, hence, poor transduction. This conclusion was further supported by a direct comparison of the CRAd DNA replication dynamics in vitro (see Figure  4D ). Wheras MDA-MB-361 cells appeared to be less permissive for the delta 24 CRAd replication , also evidenced by poor sensitivity to CRAd-mediated oncolysis in vitro (data not shown), xenograft tumors derived from MDA-MB-361 cells unexpectedly showed up to 24-fold stronger fl uorescence compared to the DY36T2 tumors following infection with either of the delta 24 CRAds (see Figure 6 and Figure 7 ). This fi nding supports the notion that some biologic properties of cancer cells can differ dramatically in vitro and in vivo.
Although an in vivo imaging study of a capsid-labeled adenovirus has been reported, 15 the feasibility of direct visualization of labeled Ad particles in tumors without contribution of the reporter gene expression and viral replication has not been addressed or demonstrated. Moreover, a conventional fl uorescent imaging was used for signal detection as opposed to more sensitive spectral imaging. Our CRAd imaging approach uniquely allowed detection of subtle changes in intensity and distribution of the CRAd particle-associated fl uorescence within the fi rst hour after IT CRAd administration. The observed reduction in signal intensity probably refl ects virus diffusion from and/ or within the tumor mass via tumor vasculature or possibly even physical disintegration of the CRAds. Detection of CRAds shortly after administration and quantifi cation of the specifi c, viral particle-associated fl uorescence provides a valuable noninvasive tool for controlling CRAd delivery and redistribution in tumor tissues prior to the onset of viral replication. Importantly, this also offers a basis for quantitative assessment of changes in IT fl uorescence levels, allowing normalization of the total tissue fl uorescence at a given time point to the input signal. Calculation of relative signal amplifi cation can be used as a means to quantitatively assess and compare CRAd replication rates in vivo.
Owing to the strong variability in the measured intensity of the tumor-injected (input) fl uorescence, we were unable to observe any signifi cant difference in fl uorescent yields between the mRFP1-and the mCherry-CRAd particles in the tumors. On the other hand, a substantial difference in infectious titers between the mCherry-and mRFP1-CRAd preparations did not allow for an accurate quantitative comparison of fl uorescent yields produced by replicating mRFP1and mCherry-CRAds in the animal tumor model either. On the other hand, if equal infectious units of each CRAd were to be used, it would result in an unequal number of tumorinjected particles (unequal input signal) and, given the signal calculation approach (as a percentage of the input fl uorescence), would lead to underestimation of the relative fl uorescence increase for the replicating mCherry-CRAd. Thus, a formally accurate comparison of the CRAd fl uorescent yields in tumors would require that both the number of replicating viral genomes and the level of input fl uorescence (number of injected labeled virions) be the same. Unfortunately, such a condition could not be met in this study.
Therefore, the only conceivable way of estimating the relative fl uorescent yields of the two CRAds in tumors was to make an approximation by normalizing all fl uorescence values obtained for the replicating viruses in tumors to equal CRAd infectious (TCID 50 ) units, assuming proportionality of the fl uorescent signals to the number of replicated viral genomes and, correspondingly, to the number of the input infectious CRAd units during the linear phase of CRAd replication. The validity of those assumptions was supported by our in vitro "simulation" experiments (see Figure 4E ).
The maximal fl uorescent yields for the mCherry-CRAd in tumors estimated with such approximation were severalfold (from 3.6-to 11-fold) higher than those for the mRFP1-CRAd depending on the tumor type (see Figure 7 , C and D, and Figure 7 , A and B, respectively) . Although the mCherry reporter appeared to provide some advantage over mRFP1, both fl uorescent reporters showed utility as imaging tags for noninvasive monitoring of CRAds in mouse models of breast cancer.
A continuous noninvasive tracking of the CRAds in breast cancer xenografts by spectral fl uorescent imaging showed a conspicuous, up to 2,000-fold increase in fl uorescence intensity relative to the input signal (see Figure 7 ). Together with the oscillating nature of each tumor's fl uorescence profi le and remarkable longevity of the signal persistence (for nearly 2 months), this observation suggested that both CRAds underwent continuous replication cycles in the tumors. CRAd replication in the xenografts was also evidenced by direct correlation of the red fl uorescence with the number of CRAd genomes, recovered from tumors at various time points of the experiment (data not shown). Thus, red fl uorescence can be effectively used to noninvasively and quantitatively monitor replication of the capsid-labeled CRAds in tumors. This fi nding is consistent with an earlier study using mRFP1-labeled Ad particles. 15 A high degree of similarity was observed between replication profi les of the mCherry-and the mRFP1-CRAds within each type of tumor (see Figure 7 , A and B, and Figure 7 , C and D), whereas substantially more difference in the profi les was noted between different tumor types (see Figure 7 , A and C, and Figure 7 , B and D). This might refl ect biochemical differences between the two types of cancer cells, resulting in drastically different ability of MDA-MB-361 cells to support the Ad5/3, delta-24 CRAd replication in vitro and in vivo.
Although the timing of the major fl uorescence peak in the CRAd replication profi les observed in this study was consistent with that observed in the previous study, 15 the longevity of the fl uorescence (viral replication) in tumors, observed in our study, was substantially longer and the oscillatory dynamics of viral replication was much more conspicuous (see Figure 7 ).
Finally, imaging of dissected tumors demonstrated an effi cient penetration of both mCherry and mRFP1 fl uorescence through the mouse skin, with only a slight signal attenuation. Much stronger signal attenuation and scatter were observed for the tumor tissue, as revealed by imaging of cross sections of tumors after slicing (see Figure 8 ). This suggests that the depth of imaging signal localization in a solid tumor is a critical factor, determining the intensity of detected fl uorescent signal. Spectral imaging of sliced tumors also provided important information regarding the signal distribution across the tumor mass (see Figure 8 ), suggesting that the viral spread in the tumor mass following IT injection was limited (see Figure 8 , panels M #8, M #6, M #7). This was consistent with the earlier observations of limited lateralization of CRAds in vivo. 15 Given that the focus of this study was primarily CRAd imaging capabilities, the oncolytic potential of the viruses in tumors was not analyzed.
Owing to the high levels of fl uorescence maintained in the tumors throughout the CRAd replication cycles from day 4 to day 17, the spectral defi nition (unmixing) capacity of the spectral imaging method was not crucial for identifi cation of the mRFP1-or mCherry-specifi c fl uorescence during this initial period of the CRAd in vivo life cycle (see Figure 6 , days 4-17). However, the spectral signature-based signal identification, uniquely provided by this method, became increasingly important at later time points when signal levels approached tissue autofl uorescence levels. The spectral unmixing function also demonstrated utility for ex vivo imaging of isolated and sliced tumors owing to high levels of background fl uorescence (see Figure 8C ).
In the aggregate, this study represents the fi rst imaging validation of a tumor-targeted CRAd agent with fl uorescently labeled capsid in an animal tumor model and for the fi rst time demonstrates the feasibility of direct visualization and quantifi cation of fl uorescent viral particles in orthotopic breast carcinoma tumors immediately or shortly after their intratumoral administration with the help of a new spectral imaging technology. This method demonstrated important utility for sensitive monitoring of fl uorescent CRAd agents and signal quantifi cation in tumors by means of circumventing the problem of tissue autofl uorescence.
Spectral imaging holds another important potential for separating the virus particle-associated fl uorescence from that of the free form of a reporter fusion owing to tentative changes in the spectral profi le of the signal that could possibly be induced by capsid incorporation of the reporter. This could allow highly specifi c monitoring of the replicating viral mass, critical for accurate tracking of replicating CRAds. This capacity could not be achieved in the present study (our unpublished observations, 2009) owing to technical limitations and would require improved resolution of the method as well as a more advanced instrumentation, which may become available in the years to come. Spectral imaging in conjunction with fl uorescent labeling of CRAd agents thus holds promise for facilitating real-time analysis of the tagged CRAds in cancer models and thereby improving the clinical effi cacy of the future virotherapy agents. This study represents the fi rst step on this path.
